Oncolytic Virus

Oncolytic Virus Comprehensive Study by Type (Natural Viruses (wild type, Naturally Variant Strains of Weak Viruses), Genetically Modified Virus Strains), Application (Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer, Others), End User (Hospitals, Healthcare Research Centers, Academics Institutions, Laboratories, Others) Players and Region - Global Market Outlook to 2028

Oncolytic Virus Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
An oncolytic virus is defined as genetically engineered or naturally occurring viruses that selectively replicate in and kill cancer cells without harming the normal tissues. Oncolytic virus therapy is perhaps the next major breakthrough in cancer treatment following the success in immunotherapy using immune checkpoint inhibitors. An oncolytic virus is recognized as a new therapeutic approach for cancer treatment, this has led to significant growth of the global oncolytic virus market in the forecast period.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledMerck & Co., Inc. (United States), Otsuka Pharmaceutical Co., Ltd. (Japan), Pfizer Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), Cold Genesys, Inc. (United States), Genelux Corporation (United States), Amgen Inc. (United States), Oncolytics Biotech Inc. (Canada), Viralytics (Australia) and Transgene SA (France)


This growth is primarily driven by Increasing chronic diseases such as cancer, diabetes, epilepsy are the major driver of the global oncolytic virus market. In recent years, the global rate of cancer incidence has increased. Cancer is still a significant factor in threatening human health. Cancer cells use high mutation to evade immune surveillance, gradually forming a low pH, low oxygen microenvironment containing proteolytic enzymes..

Globally, a noticeable market trend is evident Oncolytic Virus are used as new Therapeutic Agents in the Field of Malignant Tumor Treatment Major Players, such as Merck & Co., Inc. (United States), Otsuka Pharmaceutical Co., Ltd. (Japan), Pfizer Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), Cold Genesys, Inc. (United States), Genelux Corporation (United States), Amgen Inc. (United States), Oncolytics Biotech Inc. (Canada), Viralytics (Australia) and Transgene SA (France), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. According to Patsnap Synapse, as of 24 Sep 2023, there are a total of 364 Oncolytic virus drugs

Key Developments in the Market:
In February 2018,Merck known as MSD outside the United States and Canada, and Viralytics Limited announced that the companies have signed a definitive agreement under which it is proposed that Merck, through a subsidiary, will acquire Viralytics, an Australian publicly traded company focused on oncolytic immunotherapy treatments for a range of cancers by way of a scheme of arrangement (Scheme) for AUD 1.75 cash per Viralytics share.
In November 2021 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced that it has launched DELYTACT® (teserpaturev/G47∆)*1, an oncolytic virus developed by the, company in collaboration with Professor Tomoki Todo (hereinafter, Dr. Todo) of the Institute of Medical and Science, The University of Tokyo.

Regulatory Insights:
The Center for Biologics Evaluation and Research (CBER)/Office of Cellular, Tissue, and Gene Therapies (OCTGT) is issuing this guidance, sponsors of virus or bacteria-based gene therapy products (VBGT products) and oncolytic viruses or bacteria (oncolytic products) with recommendations on how to conduct shedding studies during preclinical and clinical development.

Influencing Trend:
Oncolytic Virus are used as new Therapeutic Agents in the Field of Malignant Tumor Treatment

Market Growth Drivers:
Increasing chronic diseases such as cancer, diabetes, epilepsy are the major driver of the global oncolytic virus market. In recent years, the global rate of cancer incidence has increased. Cancer is still a significant factor in threatening human health. Cancer cells use high mutation to evade immune surveillance, gradually forming a low pH, low oxygen microenvironment containing proteolytic enzymes.

Challenges:
Choice of virus platform.

Restraints:
Strict Government Norms and Regulations

Opportunities:
Rising Healthcare Spending in Developed and Developing Economies and Increasing Research and Development in the Cancer Drugs

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Oncolytic Virus Market
- Analysis about New Entrants in Oncolytic Virus Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Oncolytic Virus Study Sheds Light on
— The Oncolytic Virus Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Oncolytic Virus industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Oncolytic Virus industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Natural Viruses (wild type, Naturally Variant Strains of Weak Viruses)
  • Genetically Modified Virus Strains
By Application
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Melanoma
  • Brain Tumor
  • Blood Cancer
  • Others
By End User
  • Hospitals
  • Healthcare Research Centers
  • Academics Institutions
  • Laboratories
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing chronic diseases such as cancer, diabetes, epilepsy are the major driver of the global oncolytic virus market. In recent years, the global rate of cancer incidence has increased. Cancer is still a significant factor in threatening human health. Cancer cells use high mutation to evade immune surveillance, gradually forming a low pH, low oxygen microenvironment containing proteolytic enzymes.
    • 3.3. Market Challenges
      • 3.3.1. Choice of virus platform.
    • 3.4. Market Trends
      • 3.4.1. Oncolytic Virus are used as new Therapeutic Agents in the Field of Malignant Tumor Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oncolytic Virus, by Type, Application, End User and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Oncolytic Virus (Value)
      • 5.2.1. Global Oncolytic Virus by: Type (Value)
        • 5.2.1.1. Natural Viruses (wild type, Naturally Variant Strains of Weak Viruses)
        • 5.2.1.2. Genetically Modified Virus Strains
      • 5.2.2. Global Oncolytic Virus by: Application (Value)
        • 5.2.2.1. Breast Cancer
        • 5.2.2.2. Lung Cancer
        • 5.2.2.3. Prostate Cancer
        • 5.2.2.4. Melanoma
        • 5.2.2.5. Brain Tumor
        • 5.2.2.6. Blood Cancer
        • 5.2.2.7. Others
      • 5.2.3. Global Oncolytic Virus by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Healthcare Research Centers
        • 5.2.3.3. Academics Institutions
        • 5.2.3.4. Laboratories
        • 5.2.3.5. Others
      • 5.2.4. Global Oncolytic Virus Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Oncolytic Virus (Price)
      • 5.3.1. Global Oncolytic Virus by: Type (Price)
  • 6. Oncolytic Virus: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co., Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Otsuka Pharmaceutical Co., Ltd. (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cold Genesys, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Genelux Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Amgen Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Oncolytics Biotech Inc. (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Viralytics (Australia)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Transgene SA (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Oncolytic Virus Sale, by Type, Application, End User and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Oncolytic Virus (Value)
      • 7.2.1. Global Oncolytic Virus by: Type (Value)
        • 7.2.1.1. Natural Viruses (wild type, Naturally Variant Strains of Weak Viruses)
        • 7.2.1.2. Genetically Modified Virus Strains
      • 7.2.2. Global Oncolytic Virus by: Application (Value)
        • 7.2.2.1. Breast Cancer
        • 7.2.2.2. Lung Cancer
        • 7.2.2.3. Prostate Cancer
        • 7.2.2.4. Melanoma
        • 7.2.2.5. Brain Tumor
        • 7.2.2.6. Blood Cancer
        • 7.2.2.7. Others
      • 7.2.3. Global Oncolytic Virus by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Healthcare Research Centers
        • 7.2.3.3. Academics Institutions
        • 7.2.3.4. Laboratories
        • 7.2.3.5. Others
      • 7.2.4. Global Oncolytic Virus Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Oncolytic Virus (Price)
      • 7.3.1. Global Oncolytic Virus by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oncolytic Virus: by Type(USD Million)
  • Table 2. Oncolytic Virus Natural Viruses (wild type, Naturally Variant Strains of Weak Viruses) , by Region USD Million (2017-2022)
  • Table 3. Oncolytic Virus Genetically Modified Virus Strains , by Region USD Million (2017-2022)
  • Table 4. Oncolytic Virus: by Application(USD Million)
  • Table 5. Oncolytic Virus Breast Cancer , by Region USD Million (2017-2022)
  • Table 6. Oncolytic Virus Lung Cancer , by Region USD Million (2017-2022)
  • Table 7. Oncolytic Virus Prostate Cancer , by Region USD Million (2017-2022)
  • Table 8. Oncolytic Virus Melanoma , by Region USD Million (2017-2022)
  • Table 9. Oncolytic Virus Brain Tumor , by Region USD Million (2017-2022)
  • Table 10. Oncolytic Virus Blood Cancer , by Region USD Million (2017-2022)
  • Table 11. Oncolytic Virus Others , by Region USD Million (2017-2022)
  • Table 12. Oncolytic Virus: by End User(USD Million)
  • Table 13. Oncolytic Virus Hospitals , by Region USD Million (2017-2022)
  • Table 14. Oncolytic Virus Healthcare Research Centers , by Region USD Million (2017-2022)
  • Table 15. Oncolytic Virus Academics Institutions , by Region USD Million (2017-2022)
  • Table 16. Oncolytic Virus Laboratories , by Region USD Million (2017-2022)
  • Table 17. Oncolytic Virus Others , by Region USD Million (2017-2022)
  • Table 18. South America Oncolytic Virus, by Country USD Million (2017-2022)
  • Table 19. South America Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 20. South America Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 21. South America Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 22. Brazil Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 23. Brazil Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 24. Brazil Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 25. Argentina Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 26. Argentina Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 27. Argentina Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 28. Rest of South America Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 29. Rest of South America Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 30. Rest of South America Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 31. Asia Pacific Oncolytic Virus, by Country USD Million (2017-2022)
  • Table 32. Asia Pacific Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 33. Asia Pacific Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 34. Asia Pacific Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 35. China Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 36. China Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 37. China Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 38. Japan Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 39. Japan Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 40. Japan Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 41. India Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 42. India Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 43. India Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 44. South Korea Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 45. South Korea Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 46. South Korea Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 47. Taiwan Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 48. Taiwan Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 49. Taiwan Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 50. Australia Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 51. Australia Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 52. Australia Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 54. Rest of Asia-Pacific Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 55. Rest of Asia-Pacific Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 56. Europe Oncolytic Virus, by Country USD Million (2017-2022)
  • Table 57. Europe Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 58. Europe Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 59. Europe Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 60. Germany Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 61. Germany Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 62. Germany Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 63. France Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 64. France Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 65. France Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 66. Italy Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 67. Italy Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 68. Italy Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 69. United Kingdom Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 70. United Kingdom Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 71. United Kingdom Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 72. Netherlands Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 73. Netherlands Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 74. Netherlands Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 75. Rest of Europe Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 76. Rest of Europe Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 77. Rest of Europe Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 78. MEA Oncolytic Virus, by Country USD Million (2017-2022)
  • Table 79. MEA Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 80. MEA Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 81. MEA Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 82. Middle East Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 83. Middle East Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 84. Middle East Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 85. Africa Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 86. Africa Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 87. Africa Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 88. North America Oncolytic Virus, by Country USD Million (2017-2022)
  • Table 89. North America Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 90. North America Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 91. North America Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 92. United States Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 93. United States Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 94. United States Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 95. Canada Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 96. Canada Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 97. Canada Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 98. Mexico Oncolytic Virus, by Type USD Million (2017-2022)
  • Table 99. Mexico Oncolytic Virus, by Application USD Million (2017-2022)
  • Table 100. Mexico Oncolytic Virus, by End User USD Million (2017-2022)
  • Table 101. Oncolytic Virus: by Type(USD/Units)
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Oncolytic Virus: by Type(USD Million)
  • Table 113. Oncolytic Virus Natural Viruses (wild type, Naturally Variant Strains of Weak Viruses) , by Region USD Million (2023-2028)
  • Table 114. Oncolytic Virus Genetically Modified Virus Strains , by Region USD Million (2023-2028)
  • Table 115. Oncolytic Virus: by Application(USD Million)
  • Table 116. Oncolytic Virus Breast Cancer , by Region USD Million (2023-2028)
  • Table 117. Oncolytic Virus Lung Cancer , by Region USD Million (2023-2028)
  • Table 118. Oncolytic Virus Prostate Cancer , by Region USD Million (2023-2028)
  • Table 119. Oncolytic Virus Melanoma , by Region USD Million (2023-2028)
  • Table 120. Oncolytic Virus Brain Tumor , by Region USD Million (2023-2028)
  • Table 121. Oncolytic Virus Blood Cancer , by Region USD Million (2023-2028)
  • Table 122. Oncolytic Virus Others , by Region USD Million (2023-2028)
  • Table 123. Oncolytic Virus: by End User(USD Million)
  • Table 124. Oncolytic Virus Hospitals , by Region USD Million (2023-2028)
  • Table 125. Oncolytic Virus Healthcare Research Centers , by Region USD Million (2023-2028)
  • Table 126. Oncolytic Virus Academics Institutions , by Region USD Million (2023-2028)
  • Table 127. Oncolytic Virus Laboratories , by Region USD Million (2023-2028)
  • Table 128. Oncolytic Virus Others , by Region USD Million (2023-2028)
  • Table 129. South America Oncolytic Virus, by Country USD Million (2023-2028)
  • Table 130. South America Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 131. South America Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 132. South America Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 133. Brazil Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 134. Brazil Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 135. Brazil Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 136. Argentina Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 137. Argentina Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 138. Argentina Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 139. Rest of South America Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 140. Rest of South America Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 141. Rest of South America Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 142. Asia Pacific Oncolytic Virus, by Country USD Million (2023-2028)
  • Table 143. Asia Pacific Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 144. Asia Pacific Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 145. Asia Pacific Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 146. China Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 147. China Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 148. China Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 149. Japan Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 150. Japan Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 151. Japan Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 152. India Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 153. India Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 154. India Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 155. South Korea Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 156. South Korea Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 157. South Korea Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 158. Taiwan Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 159. Taiwan Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 160. Taiwan Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 161. Australia Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 162. Australia Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 163. Australia Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 164. Rest of Asia-Pacific Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 165. Rest of Asia-Pacific Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 166. Rest of Asia-Pacific Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 167. Europe Oncolytic Virus, by Country USD Million (2023-2028)
  • Table 168. Europe Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 169. Europe Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 170. Europe Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 171. Germany Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 172. Germany Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 173. Germany Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 174. France Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 175. France Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 176. France Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 177. Italy Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 178. Italy Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 179. Italy Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 180. United Kingdom Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 181. United Kingdom Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 182. United Kingdom Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 183. Netherlands Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 184. Netherlands Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 185. Netherlands Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 186. Rest of Europe Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 187. Rest of Europe Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 188. Rest of Europe Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 189. MEA Oncolytic Virus, by Country USD Million (2023-2028)
  • Table 190. MEA Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 191. MEA Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 192. MEA Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 193. Middle East Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 194. Middle East Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 195. Middle East Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 196. Africa Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 197. Africa Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 198. Africa Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 199. North America Oncolytic Virus, by Country USD Million (2023-2028)
  • Table 200. North America Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 201. North America Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 202. North America Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 203. United States Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 204. United States Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 205. United States Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 206. Canada Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 207. Canada Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 208. Canada Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 209. Mexico Oncolytic Virus, by Type USD Million (2023-2028)
  • Table 210. Mexico Oncolytic Virus, by Application USD Million (2023-2028)
  • Table 211. Mexico Oncolytic Virus, by End User USD Million (2023-2028)
  • Table 212. Oncolytic Virus: by Type(USD/Units)
  • Table 213. Research Programs/Design for This Report
  • Table 214. Key Data Information from Secondary Sources
  • Table 215. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oncolytic Virus: by Type USD Million (2017-2022)
  • Figure 5. Global Oncolytic Virus: by Application USD Million (2017-2022)
  • Figure 6. Global Oncolytic Virus: by End User USD Million (2017-2022)
  • Figure 7. South America Oncolytic Virus Share (%), by Country
  • Figure 8. Asia Pacific Oncolytic Virus Share (%), by Country
  • Figure 9. Europe Oncolytic Virus Share (%), by Country
  • Figure 10. MEA Oncolytic Virus Share (%), by Country
  • Figure 11. North America Oncolytic Virus Share (%), by Country
  • Figure 12. Global Oncolytic Virus: by Type USD/Units (2017-2022)
  • Figure 13. Global Oncolytic Virus share by Players 2022 (%)
  • Figure 14. Global Oncolytic Virus share by Players (Top 3) 2022(%)
  • Figure 15. Global Oncolytic Virus share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Merck & Co., Inc. (United States) Revenue: by Geography 2022
  • Figure 19. Otsuka Pharmaceutical Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 20. Otsuka Pharmaceutical Co., Ltd. (Japan) Revenue: by Geography 2022
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 23. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2022
  • Figure 25. Cold Genesys, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Cold Genesys, Inc. (United States) Revenue: by Geography 2022
  • Figure 27. Genelux Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. Genelux Corporation (United States) Revenue: by Geography 2022
  • Figure 29. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Amgen Inc. (United States) Revenue: by Geography 2022
  • Figure 31. Oncolytics Biotech Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 32. Oncolytics Biotech Inc. (Canada) Revenue: by Geography 2022
  • Figure 33. Viralytics (Australia) Revenue, Net Income and Gross profit
  • Figure 34. Viralytics (Australia) Revenue: by Geography 2022
  • Figure 35. Transgene SA (France) Revenue, Net Income and Gross profit
  • Figure 36. Transgene SA (France) Revenue: by Geography 2022
  • Figure 37. Global Oncolytic Virus: by Type USD Million (2023-2028)
  • Figure 38. Global Oncolytic Virus: by Application USD Million (2023-2028)
  • Figure 39. Global Oncolytic Virus: by End User USD Million (2023-2028)
  • Figure 40. South America Oncolytic Virus Share (%), by Country
  • Figure 41. Asia Pacific Oncolytic Virus Share (%), by Country
  • Figure 42. Europe Oncolytic Virus Share (%), by Country
  • Figure 43. MEA Oncolytic Virus Share (%), by Country
  • Figure 44. North America Oncolytic Virus Share (%), by Country
  • Figure 45. Global Oncolytic Virus: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Merck & Co., Inc. (United States)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Pfizer Inc. (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Cold Genesys, Inc. (United States)
  • Genelux Corporation (United States)
  • Amgen Inc. (United States)
  • Oncolytics Biotech Inc. (Canada)
  • Viralytics (Australia)
  • Transgene SA (France)
Additional players considered in the study are as follows:
Oncorus, Inc. (United States) , Valo Therapeutics LTD (Finland) , Oncolys BioPharma Inc. (United States) , Targovax (Norway) , PsiOxus Therapeutics (United Kingdom) , Jennerex Biotherapeutics, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 225 Pages 71 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Oncolytic Virus Quantitative research analysis
Oncolytic Virus Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Oncolytic Virus market are Merck & Co., Inc. (United States), Otsuka Pharmaceutical Co., Ltd. (Japan), Pfizer Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), Cold Genesys, Inc. (United States), Genelux Corporation (United States), Amgen Inc. (United States), Oncolytics Biotech Inc. (Canada), Viralytics (Australia) and Transgene SA (France), to name a few.
is dominating the Oncolytic Virus Market.
"Choice of virus platform." is seen as one of the major challenges by many Industry Players of Oncolytic Virus Market
The Oncolytic Virus market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Oncolytic Virus market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Oncolytic Virus Report?

Have a Query? Click Here

Other Related Reports

Candidiasis Therapeutics Comprehensive Study by Application (Multispecialty Hospitals, Cancer Research Institutes, Others), Drug (Polyene, Azole, Echinocandin, Other Types of Drugs), Route of Adminis...
$ 3750
Friedreich Ataxia Drug Comprehensive Study by Type (Amitriptyline or Gabapentin, Muscle Relaxants, Antidepressants), Application (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacies,...
$ 3650
Hyperthermia Treatment for Cancer Comprehensive Study by Application (Head and neck, Brain, Lung, Endometrial, Breast, Bladder, Others), Technology (Ultrasound, Electromagnetic, Microwaves, Infrared)...
$ 3650
Huntingtons Disease Therapeutics Comprehensive Study by Application (Health Care Centres, Hospitals), Distribution Channel (Online, Hospital Pharmacies), Medication Type (Antidopaminergics, Anticonvu...
$ 3450
Ebola Virus Vaccine Comprehensive Study by Type (Live-attenuated Vaccines, Inactivated Vaccines, Others), Application (Hospitals and Clinics, Charity Organization), Diagnostic Tests (ELISA, Antigen-c...
$ 3750
Chickenpox Vaccine Comprehensive Study by Type (Monovalent Vaccine, Combination Vaccine), Application (Hospitals, Clinics, Laboratories), End User (Children, Adults) Players and Region - Global Marke...
$ 3500